Pause Video
Our Product Development Pipeline
Our robust product development pipeline is built on a portfolio of proprietary and patented technology. Driven by Lisata’s vision and mission, our pipeline programs are grounded in rational science to identify and treat patients most likely to respond to our targeted therapies. Click on each program to learn more.
CendR Platform® Programs
The CendR Platform® incorporates novel technologies to enable more effective tumor-targeted, tissue penetrating delivery of anti-cancer agents to solid tumors. The Platform can also target non-cancerous, immunosuppressive cells selectively within the tumor to enable a patient’s immune system and/or immunotherapies to fight cancer more effectively.
| Indication | Pre Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
Indication: First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
||||
| ASCEND: Gemcitabine/Nab-paclitaxel with certepetide or placebo | Australia/New Zealand | ||||
| First-Line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) |
ASCEND: Gemcitabine/Nab-paclitaxel with certepetide or placebo | Australia/New Zealand
|
|
Phase 2
|
|
| Phase 1b/2a: Gemcitabine/Nab-paclitaxel + certepetide | China | ||||
|
Phase 1b/2a: Gemcitabine/Nab-paclitaxel + certepetide | China
|
Phase 1
|
|
|
|
| iLSTA: Gemcitabine/Nab-paclitaxel/Durvalumab + certepetide | Australia | ||||
|
iLSTA: Gemcitabine/Nab-paclitaxel/Durvalumab + certepetide | Australia
|
Phase 1
|
|
|
|
| Phase 2b: Gemcitabine/Nab-paclitaxel + certepetide | China | ||||
|
Phase 2b: Gemcitabine/Nab-paclitaxel + certepetide | China
|
|
Phase 2
|
|
|
Indication: Pancreatic, Colon, and Appendiceal Cancers |
||||
| CENDIFOX: FOLFIRINOX + panitumumab with certepetide | United States | ||||
| Pancreatic, Colon, and Appendiceal Cancers |
CENDIFOX: FOLFIRINOX + panitumumab with certepetide | United States
|
Phase 1
|
|
|
Indication: Cholangiocarcinoma |
||||
| BOLSTER: Gemcitabine/Cisplatin/Durvalumab with certepetide or placebo | United States | ||||
| Cholangiocarcinoma |
BOLSTER: Gemcitabine/Cisplatin/Durvalumab with certepetide or placebo | United States
|
|
Phase 2
|
|
Indication: Glioblastoma Multiforme |
||||
| Temozolomide with certepetide or placebo | Estonia/Latvia | ||||
| Glioblastoma Multiforme |
Temozolomide with certepetide or placebo | Estonia/Latvia
|
|
Phase 2
|
|
Indication: Locally advanced, non-resectable, Gastroesophageal Adenocarcinoma |
||||
| iGoLSTA: Nivolumab/FOLFIRINOX + certepetide | Australia | ||||
| Locally advanced, non-resectable, Gastroesophageal Adenocarcinoma |
iGoLSTA: Nivolumab/FOLFIRINOX + certepetide | Australia
|
Phase 1
|
|
|
Certepetide received Fast Track and Orphan Drug Designations by the U.S. FDA in Pancreatic Ductal Adenocarcinoma, Glioblastoma Multiforme, and Osteosarcoma. Certepetide also received U.S. FDA Rare Pediatric Disease Designation in Osteosarcoma.